Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma

Radiation Oncology

Volumn 4, Issue , 2009, Pages 35-

  Pehlivan, Berrin ^a   Topkan, Erkan ^a   Onal, Cem ^a   Nursal, Gul N ^a   Yuksel, Oznur ^a   Dolek, Yemliha ^a   Yavuz, Melek N ^a   Yavuz, Ali A ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT PLANNING; TUMOR VOLUME;

EID: 70449378866     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-35     Document Type: Article

References (37)

1. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989, 7:1157-1168.
2. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Cli Lung Cancer 2004, 5:290-298.
3. Dogan AU, Barýs YI, Dogan M, Emri S, Steele L, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis caues a mesothelioma epidemic in Turkey. Cancer Res 2006, 66:5063-5068. 10.1158/0008-5472.CAN-05-4642, 16707428.
4. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-suspectibility factor and malignant mesothelioma in the Cappodocian region of Turkey. Lancet 2001, 357:444-445. 10.1016/S0140-6736(00)04013-7, 11273069.
5. Yoshino I, Yamaguchi M, Okamoto T, Ushijima C, Fukuyama Y, Ichinose Y, Maehara Y. Multimodel treatment for resectable epithelial type malignant pleural mesothelioma. World J Surg Oncol 2004, 2:11. 10.1186/1477-7819-2-11, 419371, 15128453.
6. Sugarbaker D, Flores R, Jaklitsh M, Richards WG, Strauss GM, Corson JM, DeCamp MM, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 1:54-63.
7. Metintas M, Ucgun I, Elbek O, Erginel S, Metintas S, Kolsuz M, Harmancý E, Alatas F, Hillerdal G, Ozkan R, Kaya T. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol 2002, 41:1-9. 10.1016/S0720-048X(01)00426-0, 11750145.
8. Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assesment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988, 96:171-7.
9. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 2004, 4:1039-1047.
10. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998, 114:713-22. 10.1378/chest.114.3.713, 9743156.
11. Kluetz PG, Meltzer CC, Villemange VL, Kinahan PE, Chander S, Martinelli MA, Townsend DW. Combined PET/CT imaging in oncology: Impact on patient management. Clin Positron Imaging 2000, 3:223-230. 10.1016/S1095-0397(01)00055-3, 11378434.
12. Bar-Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Israel O. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003, 44:1200-1209.
13. Ciernik F, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lütolf UM, Steinert HC, Von Schulthess GK. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 2003, 57:853-863.
14. Roman CD, Martin WH, Delbeke D. Incremental value of fusion imaging with integrated PET-CT in oncology. Clin Nucl Med 2005, 30:470-477. 10.1097/01.rlu.0000167514.11891.f5, 15965321.
15. van Baardwick A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin P, De Ruysscher D. The current status of PET-FDG in tumor voulme definition in radiotherapy treatment planning. Cancer Treat Rev 2006, 32:245-60. 10.1016/j.ctrv.2006.02.002, 16563636.
16. Topkan E, Yavuz AA, Aydin M, Onal C, Yapar F, Yavuz MN. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Cancer Exp Clin Cancer Res 2008, 27:41.
17. Caretta A, Landoni C, Melloni G, Ceresolli GL, Compierchio A, Fazio F, Zannini P. 18-FDG PET in the evaluation of malignant pleural disease: a pilot study. Eur J Cardiovasc Surg 2000, 17:377-383.
18. Plathow C, Staab A, Schmaehl A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, Eschmann S, Kloop M. Computed tomography, positron emission tomograpy, positron emission tomograpy/computed tomography, and magnetic resonance imaging for staging of limited pleural meothelioma. Invest Radiol 2008, 43:737-744. 10.1097/RLI.0b013e3181817b3d, 18791416.
19. International Mesothelioma Interest Group A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108:1122-8. 10.1378/chest.108.4.1122, 7555126.
20. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002, 62:51-60. 10.1016/S0167-8140(01)00470-4, 11830312.
21. Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Healy-Baldini E, DeCamp MM, Mentzer SJ, Liptay MJ, Strauss GM, Swansob SJ. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: Results in 120 consecutive patients. Ann Surg 1996, 224:288-294. 10.1097/00000658-199609000-00005, 1235368, 8813257.
22. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Cardiovasc Surg 2004, 128:138-146.
23. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991, 102:1-9.
24. Perrot M, Feld R, Cho BCJ, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR. Trimodality therapy with inductin chemotherapy followed by extrapleural pnemonectomy and adjuvant high-dose extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:1413-1418. 10.1200/JCO.2008.17.5604, 19224855.
25. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase III trial. J Thorac Oncol 2006, 1:289-295. 10.1097/01243894-200605000-00004, 17409872.
26. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788-795. 10.1067/mtc.2001.116560, 11581615.
27. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009,
28. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: Review of 1 5- year experience, with special reference to radiotherapy. Am J Clin Oncol 1990, 13:4-9. 10.1097/00000421-199002000-00002, 1689538.
29. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: A nonrandomized phase II study. Eur Respir J 1996, 9:2565-2572. 10.1183/09031936.96.09122565, 8980970.
30. Mohan R. Dueling technologies: In regard to Ling et al. (Int J Radiat Oncol Biol Phys 2008;72:575-581). Int J Radiat Oncol Biol Phys 2009, 75(1):6-7.
31. McCutchen KW, Watkins JM, Eberts P, Terwilliger LE, Ashenafi MS, Jenrette JM. Helical tomotherapy for total lymphoid irradiation. Radiat Med 2008, 26:622-6. 10.1007/s11604-008-0281-4, 19132495.
32. Shi C, Penagaricano J, Papanikolaou N. Comparison of IMRT treatment plans between linac and helical tomotherapy based on integral dose and inhomogenity index. Med Dosim 2008, 33:215-21. 10.1016/j.meddos.2007.11.001, 18674686.
33. Sterzing F, Sroka-Perez G, Schubert K, Münter MW, Thieke C, Huber P, Debus J, Herfarth KK. Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma helical tomotherapy compared with step-and-shoot IMRT. Radiother Oncol 2008, 86:251-7. 10.1016/j.radonc.2007.12.010, 18207597.
34. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, McNeil BJ. CT and MR imaging in staging non-small cell bronchogenic carcinoma report of the Radiologic Diagnostic Oncology Group. Radiology 1991, 178:705-713.
35. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lütolf UM, Steinert HC, Von Schulthess GK. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2002, 52:339-50.
36. Carlo G, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumor volume definition in radiotherapy planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007, 57:125-134. 10.1016/j.lungcan.2007.03.020, 17478008.
37. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ. Impact of FDG-PET on radiation therapy volume definition in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59:78-86.